Codiak BioSciences, Inc. (CDAK)
|Net Income (ttm)||-94.46M|
|Trading Day||January 22|
|Day's Range||25.17 - 27.90|
|52-Week Range||7.90 - 32.30|
Codiak's Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
– exoIL-12 resulted in no local or systemic treatment-related adverse events –
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a n...
– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...
Codiak BioSciences is harnessing exosomes?natural intercellular messengers?to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including i... [Read more...]
|IPO Date |
Oct 14, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 31.58% from the latest price.